Effects of Castration, Estrogen, and Androgen Administration-Reference-Cited by-同舟云学术

Effects of Castration, Estrogen, and Androgen Administration

Published:1983 Issue: Volume: Page:229-234
ISSN:
Container-title:Benign Prostatic Hypertrophy
language:
Short-container-title:

Author:

Lee Chung,Jesik Charmayne

Publisher

Springer New York

Link

http://link.springer.com/content/pdf/10.1007/978-1-4612-5476-8_20

Reference77 articles.

1. Aragona C, Friesen HG: Specific prolactin binding sites in the prostate and testis of rats. Endocrinology 97: 677–684, 1975

2. Bard DR, Laznitzki I: The influence of oestradiol on the metabolism of androgens by human prostatic tissue. J Endocrinol 74: 1–9, 1977

3. Barkey RJ, Shani J, Smit T, Barzilai D: Specific binding of prolactin to seminal vesicle, prostate and testicular homogenates of immature, mature and aged rats. J Endocrinol 74: 163–173, 1977

4. Bartsch G, Oberholzer M, Rohr HP: The effect of antiestrogen, antiandrogen, and the prolactin inhibitor 2-bromo-alpha ergocriptine on the stromal tissue of human benign prostatic hyperplasia: correlation of stereological data and plasma hormones. Invest Urol 18: 308–312, 1981

5. Bashirelahi N, Kneussl ES, Vassil TC, Young JD Jr, Sanefugi H, Trump B: Measurement and characterization of estrogen receptors in the human prostate. Prog Clin Biol Res 33: 65–84, 1979

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of Mepartricin, a polyene macrolide agent, on fecal excretion and serum concentration of estrogen and number of prostatic estrogen receptors in immature rats;The Prostate;1999-01-01

2. Aromatase mRNA Levels in Benign Prostatic Hyperplasia and Prostate Cancer;International Journal of Urology;1996-07

3. Aetiological Factors in Benign Prostatic Hyperplasia;Epidemiology of Prostate Disease;1995

4. Prostatic Cancer — Immunohistochemistry of Steroid Hormone Receptors;Current Topics in Pathology;1991

5. Selective inhibition of androstenedione-induced prostate growth in intact beagle dogs by a combined treatment with the antiandrogen cyproterone acetate and the aromatase inhibitor 1-methyl-androsta-1,4-diene-3,17-dione (1-methyl-ADD);The Prostate;1989